Overview

A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients

Status:
Completed
Trial end date:
2018-05-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of rivaroxaban compared with placebo in the prevention of symptomatic venous thromboembolism (VTE) events and VTE-related death post-hospital discharge in high-risk, medically ill patients.
Phase:
Phase 3
Details
Lead Sponsor:
Janssen Research & Development, LLC
Collaborator:
Bayer
Treatments:
Rivaroxaban